These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32503945)

  • 1. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity.
    Reches A; Ophir Y; Stein N; Kol I; Isaacson B; Charpak Amikam Y; Elnekave A; Tsukerman P; Kucan Brlic P; Lenac T; Seliger B; Jonjic S; Mandelboim O
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
    Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
    Front Immunol; 2022; 13():828319. PubMed ID: 35273608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
    Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
    J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction.
    Reymond N; Fabre S; Lecocq E; Adelaïde J; Dubreuil P; Lopez M
    J Biol Chem; 2001 Nov; 276(46):43205-15. PubMed ID: 11544254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy.
    Zhou X; Zuo C; Li W; Shi W; Zhou X; Wang H; Chen S; Du J; Chen G; Zhai W; Zhao W; Wu Y; Qi Y; Liu L; Gao Y
    Angew Chem Int Ed Engl; 2020 Aug; 59(35):15114-15118. PubMed ID: 32386245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
    Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
    Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
    Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
    Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
    Front Immunol; 2020; 11():573405. PubMed ID: 33117369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
    Preillon J; Cuende J; Rabolli V; Garnero L; Mercier M; Wald N; Pappalardo A; Denies S; Jamart D; Michaux AC; Pirson R; Pitard V; Bagot M; Prasad S; Houthuys E; Brouwer M; Marillier R; Lambolez F; Marchante JR; Nyawouame F; Carter MJ; Baron-Bodo V; Marie-Cardine A; Cragg M; Déchanet-Merville J; Driessens G; Hoofd C
    Mol Cancer Ther; 2021 Jan; 20(1):121-131. PubMed ID: 33277440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
    Wu J; Ren D; Bi H; Yi B; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
    Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
    Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional characterization of a monoclonal antibody blocking TIGIT.
    Jeong BS; Nam H; Lee J; Park HY; Cho KJ; Sheen JH; Song E; Oh M; Lee S; Choi H; Yang JE; Kim M; Oh BH
    MAbs; 2022; 14(1):2013750. PubMed ID: 35090381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.